Progyny (PGNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does ADC Therapeutics SA (ADCT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback